{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:07Z","timestamp":1794072967704,"version":"4.8.0"},"reference-count":80,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated virus\u2013based gene therapy (valoctocogene roxaparvovec) is an attractive treatment for hemophilia A. Careful clinical management is required to minimize the risk of hepatotoxicity, including assessment of baseline liver condition to determine treatment eligibility and monitoring liver function after gene therapy. This article describes recommendations (developed by a group of hemophilia experts) on hepatic function monitoring before and after gene therapy. To prevent harmful liver-related effects, gene therapy is contraindicated in patients with uncontrolled liver infections, autoimmune hepatitis, liver stiffness \u22658\u00a0kPa, or cirrhosis. Before using gene therapy in patients with liver steatosis or other liver disorders, the risk of liver damage should be considered using a highly individualized approach. Treatment is not recommended in patients with abnormal liver enzymes, including alanine aminotransferase (ALT) at any level above the upper limit of normal (ULN). Therefore, pretreatment assessment of liver health should include laboratory tests, abdominal ultrasound, and liver stiffness measurements by transient elastography (TE). In the first year after therapy, ALT levels should be monitored 1 to 2 times per week to detect elevations \u22651.5\u00d7 ULN, which may require immunosuppressant therapy. Patients with ALT elevation should receive prednisone 60\u00a0mg\/d for 2\u00a0weeks, followed by stepwise tapering when ALT returns to baseline. ALT monitoring should continue long term (every 3-6\u00a0months), along with abdominal ultrasound (every 6\u00a0months) and TE (yearly) evaluations. When patients with good liver health are selected for treatment and closely monitored thereafter, ALT elevations can be promptly treated and are expected to resolve without long-term hepatic sequelae.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013750","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T19:38:28Z","timestamp":1725392308000},"page":"5725-5734","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-7184","authenticated-orcid":false,"given":"Vincenzo","family":"La Mura","sequence":"first","affiliation":[{"name":"1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0234-3341","authenticated-orcid":false,"given":"Vincenzo","family":"Cardinale","sequence":"additional","affiliation":[{"name":"3Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Universit\u00e0 di Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8066-8849","authenticated-orcid":false,"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"4Servizio Malattie Emorragiche e Trombotiche, Dipartimento di Medicina e Chirurgia Traslazionale, Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS, Universit\u00e0 Cattolica S. Cuore Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7338-9203","authenticated-orcid":false,"given":"Adriano","family":"De Santis","sequence":"additional","affiliation":[{"name":"3Dipartimento di Medicina Traslazionale e di Precisione, Sapienza Universit\u00e0 di Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4235-7166","authenticated-orcid":false,"given":"Giovanni","family":"Di Minno","sequence":"additional","affiliation":[{"name":"5Regional Reference Centre for Hemo-Coagulation Diseases, Federico II University, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-6317","authenticated-orcid":false,"given":"Luca","family":"Fabris","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Clinical Medicine 1, University-Hospital of Padua, Padua, Italy"},{"name":"7Department of Internal Medicine, Digestive Disease Section, Yale Liver Center, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-0878","authenticated-orcid":false,"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[{"name":"8Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1537-5034","authenticated-orcid":false,"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[{"name":"9Department of Clinical Medicine and Surgery, Liver and Biliary Diseases Unit, University Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-7980","authenticated-orcid":false,"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[{"name":"10UOC Medicina Interna e del Trapianto di Fegato, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, Universit\u00e0 Cattolica del S. Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-447X","authenticated-orcid":false,"given":"Cristina","family":"Santoro","sequence":"additional","affiliation":[{"name":"11Department of Hematology, University Hospital Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-1155","authenticated-orcid":false,"given":"Ezio","family":"Zanon","sequence":"additional","affiliation":[{"name":"12Hemophilia Centre, Clinical Medicine 1, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"13Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"1","key":"2024121621110882200_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"18","key":"2024121621110882200_bib2","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.3390\/ijms231810228","article-title":"The arrival of gene therapy for patients with hemophilia A","volume":"23","author":"Castaman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024121621110882200_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.11.014","article-title":"Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists","volume":"78","author":"Miesbach","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"2024121621110882200_bib4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40259-023-00615-4","article-title":"Evaluating gene therapy as a potential paradigm shift in treating severe hemophilia","volume":"37","author":"Thornburg","year":"2023","journal-title":"BioDrugs"},{"issue":"6","key":"2024121621110882200_bib5","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4\u00a0weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"2024121621110882200_bib6","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1016\/j.rpth.2023.100077","article-title":"Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis","volume":"7","author":"Pipe","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2024121621110882200_bib7","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.ymthe.2022.08.001","article-title":"AAV and hepatitis: cause or coincidence?","volume":"30","author":"de Jong","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"2024121621110882200_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"9","key":"2024121621110882200_bib9","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.jhepr.2023.100787","article-title":"Aetiology of acute hepatitis of unknown in children, association with AAV2 and controversies","volume":"5","author":"Qi","year":"2023","journal-title":"JHEP Rep"},{"key":"2024121621110882200_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"issue":"1","key":"2024121621110882200_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2021000254","article-title":"Hemophilia gene therapy: ushering in a new treatment paradigm?","volume":"2021","author":"George","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2024121621110882200_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"51-52","key":"2024121621110882200_bib13","first-page":"887","article-title":"Gene therapy for hemophilia-opportunities and risks","volume":"119","author":"Miesbach","year":"2022","journal-title":"Dtsch Arztebl Int"},{"issue":"11","key":"2024121621110882200_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024121621110882200_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ymthe.2023.03.001","article-title":"Two gene therapies for hemophilia available: now what?","volume":"31","author":"Pierce","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"2024121621110882200_bib16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024121621110882200_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"2024121621110882200_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"issue":"26","key":"2024121621110882200_bib19","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024121621110882200_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2024121621110882200_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 6","key":"2024121621110882200_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2024121621110882200_bib23","author":"ROCTAVIAN","year":"2023"},{"key":"2024121621110882200_bib24","unstructured":"ROCTAVIAN\n          . Prescribing information. US Food and Drug Administration; 2023. Accessed 25 September 2023. https:\/\/www.fda.gov\/media\/169937\/download#:\u223c:text=Dose-,The%20recommended%20dose%20of%20ROCTAVIAN%20is%206%20%C3%97%201013%20vector,rate%20of%204%20mL%2Fmin."},{"key":"2024121621110882200_bib25","doi-asserted-by":"crossref","first-page":"20406207221145627","DOI":"10.1177\/20406207221145627","article-title":"How to translate and implement the current science of gene therapy into haemophilia care?","volume":"14","author":"Hermans","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2024121621110882200_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-a need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2024121621110882200_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles\u2013Diaz","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"2024121621110882200_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMe2212347","article-title":"Hemophilia A gene therapy - some answers, more questions","volume":"388","author":"George","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024121621110882200_bib29","first-page":"e43973","article-title":"Advances in understanding and managing autoimmune hepatitis: a narrative review","volume":"15","author":"Yadav","year":"2023","journal-title":"Cureus"},{"issue":"7","key":"2024121621110882200_bib30","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"2024121621110882200_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/iep.12264","article-title":"Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model","volume":"99","author":"Mishra","year":"2018","journal-title":"Int J Exp Pathol"},{"issue":"3","key":"2024121621110882200_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"European Association for the Study of the Liver Electronic address easloffice@easlofficeeu","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"2024121621110882200_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0033-1354421","article-title":"Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?","volume":"39","author":"Coppola","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"2024121621110882200_bib34","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv"},{"key":"2024121621110882200_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejim.2017.05.012","article-title":"Progress in the contemporary management of hemophilia: the new issue of patient aging","volume":"43","author":"Mannucci","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2024121621110882200_bib36","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/JMDH.S363177","article-title":"Hepatitis C virus infections in patients with hemophilia: links, risks and management","volume":"15","author":"Spanoudaki","year":"2022","journal-title":"J\u00a0Multidiscip Healthc"},{"issue":"2","key":"2024121621110882200_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"2024121621110882200_bib38","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.3390\/nu15112521","article-title":"Type 2 diabetes mellitus and liver disease: across the gut-liver axis from fibrosis to cancer","volume":"15","author":"Manilla","year":"2023","journal-title":"Nutrients"},{"issue":"5","key":"2024121621110882200_bib39","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"17","key":"2024121621110882200_bib40","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"2024121621110882200_bib41","doi-asserted-by":"crossref","first-page":"101626","DOI":"10.1016\/j.clinre.2021.101626","article-title":"HCV virology and diagnosis","volume":"45","author":"Roger","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"2024121621110882200_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2024121621110882200_bib43","doi-asserted-by":"crossref","first-page":"e00046-19","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2024121621110882200_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.gtc.2020.01.002","article-title":"Hepatitis A: epidemiology, natural history, unusual clinical manifestations, and prevention","volume":"49","author":"Abutaleb","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"11","key":"2024121621110882200_bib45","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","article-title":"Abnormal liver enzymes: a review for clinicians","volume":"13","author":"Kalas","year":"2021","journal-title":"World J Hepatol"},{"key":"2024121621110882200_bib46","author":"Lala","year":"2023"},{"key":"2024121621110882200_bib47","author":"Benner","year":"2024"},{"issue":"6","key":"2024121621110882200_bib48","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.3390\/ijms22063113","article-title":"Till death do us part-the multifaceted role of platelets in liver diseases","volume":"22","author":"Mussbacher","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2024121621110882200_bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.34172\/mejdd.2020.182","article-title":"Upper normal limits of serum alanine aminotransferase in healthy population: a systematic review","volume":"12","author":"Kolahdoozan","year":"2020","journal-title":"Middle East J Dig Dis"},{"issue":"5","key":"2024121621110882200_bib50","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2014.12835","article-title":"Evaluating elevated bilirubin levels in asymptomatic adults","volume":"313","author":"VanWagner","year":"2015","journal-title":"JAMA"},{"key":"2024121621110882200_bib51","author":"Adigun","year":"2024"},{"issue":"1126","key":"2024121621110882200_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/postgradmedj-2018-136111","article-title":"Multiparametric ultrasound in liver diseases: an overview for the practising clinician","volume":"95","author":"Grgurevic","year":"2019","journal-title":"Postgrad Med J"},{"key":"2024121621110882200_bib53","author":"El-Nakeep","year":"2024"},{"issue":"8","key":"2024121621110882200_bib54","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/v15081730","article-title":"Non-invasive measurement of hepatic fibrosis by transient elastography: a narrative review","volume":"15","author":"Rinaldi","year":"2023","journal-title":"Viruses"},{"issue":"9","key":"2024121621110882200_bib55","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/life10090198","article-title":"Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syndrome","volume":"10","author":"Han","year":"2020","journal-title":"Life"},{"key":"2024121621110882200_bib56","doi-asserted-by":"crossref","first-page":"101118","DOI":"10.1016\/j.blre.2023.101118","article-title":"Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline","volume":"62","author":"Di Minno","year":"2023","journal-title":"Blood Rev"},{"issue":"10","key":"2024121621110882200_bib57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2024121621110882200_bib58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"11","key":"2024121621110882200_bib59","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/diagnostics10110940","article-title":"Diagnostic accuracy of fibroscan and factors affecting measurements","volume":"10","author":"Oeda","year":"2020","journal-title":"Diagnostics"},{"issue":"2","key":"2024121621110882200_bib60","first-page":"147","article-title":"Alcoholic liver disease: pathogenesis and current management","volume":"38","author":"Osna","year":"2017","journal-title":"Alcohol Res"},{"key":"2024121621110882200_bib61","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/DMSO.S247379","article-title":"Glucocorticoid-induced fatty liver disease","volume":"13","author":"Rahimi","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"2024121621110882200_bib62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"s 01","key":"2024121621110882200_bib63","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1055\/a-1282-2286","article-title":"Molecular profiling of liver sinusoidal endothelial cells in comparison to hepatocytes: reflection on which cell type should be the target for gene therapy","volume":"40","author":"El-Maarri","year":"2020","journal-title":"H\u00e4mostaseologie"},{"issue":"21","key":"2024121621110882200_bib64","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2020005450","article-title":"Clogging up the pipeline: factor VIII aggregates","volume":"135","author":"Sabatino","year":"2020","journal-title":"Blood"},{"issue":"s1","key":"2024121621110882200_bib65","first-page":"22","article-title":"Human liver biopsy analysis reveals lower RNA transcription may contribute to a decline in FVIII levels following AAV5-hFVIII-SQ gene therapy","volume":"30","author":"Ismail","year":"2024","journal-title":"Haemophilia"},{"key":"2024121621110882200_bib66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.omto.2021.01.014","article-title":"HDAC inhibition prevents transgene expression downregulation and loss-of-function in T cell-receptor-transduced T cells","volume":"20","author":"Moore","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"2024121621110882200_bib67","first-page":"559","article-title":"Gene therapy and hemophilia: where do we go from here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J\u00a0Blood Med"},{"issue":"4","key":"2024121621110882200_bib68","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"issue":"3","key":"2024121621110882200_bib69","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"1-3","key":"2024121621110882200_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejphar.2009.06.064","article-title":"Targeting the endoplasmic reticulum-stress response as an anticancer strategy","volume":"625","author":"Healy","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2024121621110882200_bib71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.15430\/JCP.2014.19.2.75","article-title":"Endoplasmic reticulum stress and cancer","volume":"19","author":"Yadav","year":"2014","journal-title":"J\u00a0Cancer Prev"},{"issue":"12","key":"2024121621110882200_bib72","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"issue":"5","key":"2024121621110882200_bib73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.mcna.2015.05.001","article-title":"Comprehensive care of patients with chronic liver disease","volume":"99","author":"James","year":"2015","journal-title":"Med Clin North Am"},{"issue":"1","key":"2024121621110882200_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s43055-023-00982-6","article-title":"Diagnostic accuracy of ultrasound and alpha-fetoprotein measurement for hepatocellular carcinoma surveillance: a retrospective comparative study","volume":"54","author":"Abduljabbar","year":"2023","journal-title":"Egypt J Radiol Nucl Med"},{"key":"2024121621110882200_bib75","first-page":"1","article-title":"Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"issue":"suppl","key":"2024121621110882200_bib76","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2024121621110882200_bib77","doi-asserted-by":"crossref","first-page":"10760296221128294","DOI":"10.1177\/10760296221128294","article-title":"Prevalence of non-alcoholic fatty liver disease and associated factors in patients with moderate or severe hemophilia: a multicenter-based study","volume":"28","author":"Shen","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"2024121621110882200_bib78","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024121621110882200_bib79","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.jtha.2023.04.030","article-title":"\"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists\": reply","volume":"21","author":"Miesbach","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024121621110882200_bib80","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jtha.2023.04.029","article-title":"\"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists\": comment","volume":"21","author":"Puetz","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5725\/2343158\/blooda_adv-2024-013750-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5725\/2343158\/blooda_adv-2024-013750-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T21:11:32Z","timestamp":1734383492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5725\/517655\/Liver-related-aspects-of-valoctocogene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":80,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013750","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}